J. Spicer

发表

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.

D. Lane, D. Barnes, S. Picksley, 1996, Acta oncologica.

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

A. Hackshaw, M. Nicolson, J. Spicer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The challenges of integrating molecular imaging into the optimization of cancer therapy.

V. Goh, P. Ellis, T. Schaeffter, 2011, Integrative biology : quantitative biosciences from nano to macro.

IgE immunotherapy

J. Spicer, D. Josephs, S. Karagiannis, 2014, mAbs.

IgE Antibodies against Cancer: Efficacy and Safety

J. Spicer, D. Josephs, S. Karagiannis, 2020, Antibodies.

Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England

A. Purushotham, J. Spicer, A. Aggarwal, 2021, Journal of Cancer Policy.

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

U. Dafni, R. Stahel, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

J. Peto, T. Treasure, D. Landau, 2011, The Lancet. Oncology.

Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals

D. Landau, J. Spicer, P. Cane, 2012, General Thoracic and Cardiovascular Surgery.

Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma

D. Landau, S. Barrington, S. Rankin, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study

J. Peto, T. Treasure, D. Landau, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

M. Gleeson, E. Sawyer, S. Irshad, 2020, Frontiers in Oncology.

Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome

Kristina M. Ilieva, J. Spicer, S. Till, 2020, Cells.

IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype

Elmira Amiri Souri, S. Tsoka, J. Spicer, 2020, Cancers.

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Kristina M. Ilieva, S. Tsoka, D. Dombrowicz, 2017, Cancer research.

Cancer Therapy : Clinical A Phase 1 Study of AS 1409 , a Novel Antibody-Cytokine Fusion Protein , in Patients with Malignant Melanoma or Renal Cell Carcinoma

G. Acton, J. Spicer, D. Jodrell, 2011 .

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

P. Ellis, J. Spicer, 2007, Cancer letters.

Adjuvant trastuzumab for HER2-positive breast cancer

P. Ellis, J. Spicer, M. Harries, 2005, The Lancet.

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.

K. Nackaerts, L. Kasten, S. Novello, 2022, The Lancet. Oncology.

Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

A. Coolen, P. Vantourout, A. Hayday, 2021, Cancer Cell.

Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.

J. Spicer, J. Maher, Georgina F Osborne, 2017, Cancer letters.

Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4*

J. Spicer, J. Maher, David M. Davies, 2010, The Journal of Biological Chemistry.

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

J. Cochran, J. Spicer, L. Whilding, 2017, Oncoimmunology.

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

F. Khuri, R. Salgia, G. Shapiro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI‐mediated basophil activation by a tumour‐specific IgE antibody to evaluate the risk of type I hypersensitivity

F. Nestle, S. Canevari, J. Spicer, 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

A. Purushotham, B. Rachet, J. Spicer, 2020, The Lancet Oncology.

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma

D. Landau, E. Mclean, J. Spicer, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

D. Landau, J. Spicer, P. Cane, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer

C. Lewis, N. Prescott, J. Sanderson, 2018, PloS one.

18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer.

V. Goh, J. Spicer, M. Subesinghe, 2022, Radiology.

Unilateral diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and multiple carcinoids treated with surgical resection.

S. Irshad, E. Mclean, S. Barrington, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography–computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication

D. Landau, J. Spicer, S. Chicklore, 2013, Nuclear medicine communications.

OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma

K. Nackaerts, S. Novello, G. Ceresoli, 2017 .

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

M. Coffey, V. Roulstone, A. Melcher, 2014, Clinical Cancer Research.

Combination therapy versus single agent chemotherapy in non-small cell lung cancer

J. Spicer, S. Chowdhury, P. Harper, 2005, Expert opinion on pharmacotherapy.

Epidemiological associations of allergy, IgE and cancer

J. Spicer, D. Josephs, S. Karagiannis, 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

S. Irshad, M. Uttenreuther-Fischer, J. Spicer, 2016, Cancer Chemotherapy and Pharmacology.

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

A. Tutt, J. Spicer, S. Karagiannis, 2020, Scientific Reports.

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

J. Spicer, D. Mukherji, 2009, Expert opinion on investigational drugs.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

Xidong Jin, M. Uttenreuther-Fischer, J. Spicer, 2018, Cancer Chemotherapy and Pharmacology.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

M. Uttenreuther-Fischer, J. Spicer, S. Rudman, 2015, European journal of cancer.

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

R. Plummer, E. Frenkel, S. Matsumoto, 2015, European journal of cancer.

Clinical Cancer esearch cer Therapy : Clinical-10 : A Phase I Study of Intravenous Reovirus and R etaxel in Patients with Advanced Cancer

G. Nuovo, M. Coffey, K. Twigger, 2010 .

Effect of patient socioeconomic status on access to early-phase cancer trials.

J. Spicer, H. Møller, A. Suder, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

M. Gleeson, E. Sawyer, S. Irshad, 2020, Frontiers in Oncology.

Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer

D. Landau, E. Miles, J. Spicer, 2019, International journal of radiation oncology, biology, physics.

EGFR-mutated lung cancer in Li-Fraumeni syndrome.

J. Spicer, K. Tobal, P. Cane, 2014, Lung cancer.

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Kristina M. Ilieva, A. Tutt, S. Tsoka, 2018, Front. Immunol..

Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer.

J. Spicer, A. Gualberto, J. D. de Bono, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies

J. Spicer, D. Josephs, S. Karagiannis, 2021, Clinical and experimental immunology.

LKB1 Kinase: Master and Commander of Metabolism and Polarity

A. Ashworth, J. Spicer, 2004, Current Biology.

Amplification and Over-Expression of the MDM2 Gene in Human Soft Tissue Tumours

C. Cooper, B. Gusterson, C. Fisher, 1997, Sarcoma.

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma

P. Jackson, J. Spicer, S. Karagiannis, 2020, Cancers.

HOX transcription factors are potential targets and markers in malignant mesothelioma

R. Morgan, H. Pandha, K. Harrington, 2016, BMC Cancer.

Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments

J. Spicer, D. Josephs, S. Karagiannis, 2021, Cancers.

Enriched circulating and tumor-resident TGF-β+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs

S. Tsoka, J. Spicer, S. Karagiannis, 2022, Oncoimmunology.

Clinical and Translational Significance of Basophils in Patients with Cancer

J. Spicer, D. Josephs, S. Karagiannis, 2022, Cells.

Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.

J. Spicer, 2005, Current opinion in molecular therapeutics.

LBA2_PREGFR MUTATION TESTING AND ONCOLOGIST TREATMENT CHOICE IN ADVANCED NSCLC: GLOBAL TRENDS AND DIFFERENCES

J. Spicer, M. Peters, B. Tischer, 2015 .

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

M. Rubin, A. Wyatt, H. Beltran, 2022, NAR cancer.

AllergoOncology – the impact of allergy in oncology: EAACI position paper

M. Penichet, D. Dombrowicz, E. Fiebiger, 2017, Allergy.

Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients

C. Bokemeyer, J. Spicer, S. Karagiannis, 2021, Clinical and experimental immunology.

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency

A. Bradwell, J. Spicer, D. Josephs, 2014, mAbs.

Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti‐tumor IgE therapeutic candidate

Kristina M. Ilieva, S. Pinder, J. Spicer, 2020, Allergy.

Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer.

J. Spicer, D. Josephs, S. Karagiannis, 2020, Trends in molecular medicine.

AllergoOncology: Expression platform development and functional profiling of an anti‐HER2 IgE antibody

Kristina M. Ilieva, A. Tutt, J. Spicer, 2019, Allergy.

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application

F. Nestle, J. Spicer, A. Beavil, 2012, Cancer Immunology, Immunotherapy.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

J. Spicer, T. Yap, A. Gualberto, 2010, British Journal of Cancer.

First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015 .

Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced

G. Shapiro, E. Kwak, J. Bendell, 2015 .

IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states

Kristina M. Ilieva, S. Tsoka, J. Spicer, 2019, EBioMedicine.

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

J. Spicer, D. Sarker, E. Jordan, 2018, Oncotarget.

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

E. Sawyer, J. Spicer, D. Josephs, 2022, Cancers.

Effect of onartuzumab added to erlotinib on metastasis in patients with lung cancer.

J. Spicer, D. Josephs, A. Soultati, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

G. Acton, J. Spicer, D. Jodrell, 2011, Clinical Cancer Research.

IgG4 subclass antibodies impair antitumor immunity in melanoma

F. Nestle, J. Spicer, C. Hobbs, 2013 .

IgG4 subclass antibodies impair antitumor immunity in melanoma.

F. Nestle, J. Spicer, C. Hobbs, 2013, The Journal of clinical investigation.

Beta-glucan contamination of pharmaceutical products: How much should we accept?

J. Spicer, D. Josephs, S. Karagiannis, 2016, Cancer Immunology, Immunotherapy.

Cancer Therapy : Clinical A Phase 1 Study of AS 1409 , a Novel Antibody-Cytokine Fusion Protein , in Patients with Malignant Melanoma or Renal Cell Carcinoma

G. Acton, J. Spicer, D. Jodrell, 2011 .

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

R. Plummer, A. Italiano, L. Dirix, 2018, Advances in Therapy.

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.

U. Dafni, R. Stahel, A. Addeo, 2022, Lung cancer.

A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.

R. Agarwal, U. Banerji, J. Spicer, 2012 .

A Brief Report on the Safety Study of Induction Chemotherapy Followed by Synchronous Radiotherapy and Cetuximab in Stage III Non-small Cell Lung Cancer (NSCLC): SCRATCH Study

J. Shamash, D. Landau, S. Hughes, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

S. Pinder, S. Tsoka, S. Canevari, 2022, British Journal of Cancer.

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model

Kristina M. Ilieva, J. Spicer, C. Hobbs, 2019, mAbs.

An immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE

Kristina M. Ilieva, S. Tsoka, D. Dombrowicz, 2018, Allergy.

Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.

J. Spicer, D. Josephs, S. Karagiannis, 2017, Cancer research.

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

K. Harrington, U. Banerji, J. Spicer, 2018, Clinical and translational radiation oncology.

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

A. Italiano, J. Bonneterre, M. Campone, 2019, Breast Cancer Research.

Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.

R. Plummer, G. Shapiro, P. LoRusso, 2013 .

An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography–tandem mass spectrometry

L. Couchman, R. Flanagan, J. Spicer, 2012, Analytical and Bioanalytical Chemistry.

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

M. Malim, A. Hayday, S. Irshad, 2021, The Lancet Oncology.

Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies

F. Nestle, J. Spicer, A. Beavil, 2011, PloS one.

The Evolving Landscape of Cancer Therapeutics.

J. Spicer, Madeha Khan, 2019, Handbook of experimental pharmacology.

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2

E. Diamandis, J. Spicer, D. Josephs, 2021, Journal for ImmunoTherapy of Cancer.

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma

Daniel C. Scotto, Elmira Amiri Souri, S. Tsoka, 2019, Oncoimmunology.

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer.

J. Spicer, M. van Schalkwyk, J. Maher, 2013, Human gene therapy. Clinical development.

Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action

S. Tsoka, J. Spicer, D. Josephs, 2021, European journal of immunology.

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

R. Plummer, J. Machiels, D. Hong, 2019, The Lancet. Oncology.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

R. Plummer, J. Spicer, V. Diéras, 2017, British Journal of Cancer.

Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.

R. Motzer, M. Mazumdar, D. Bajorin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Routine EGFR and KRAS Mutation analysis using COLD‐PCR in non‐small cell lung cancer

J. Spicer, K. Tobal, P. Cane, 2012, International journal of clinical practice.

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

R. Doebele, E. Berge, D. Camidge, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations

J. Sanderson, S. Newhouse, J. Spicer, 2014, The Pharmacogenomics Journal.

LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1.

A. Ashworth, J. Spicer, S. Rayter, 2001, Human molecular genetics.

Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.

J. Spicer, S. Popat, P. Hall, 2015, Future oncology.

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

S. Tavaré, M. Loda, A. Tutt, 2021, Cancer cell.

Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer

J. Spicer, J. N. Arnold, James W. Opzoomer, 2019, Front. Immunol..

Development of downstream processing to minimize beta‐glucan impurities in GMP‐manufactured therapeutic antibodies

J. Spicer, D. Josephs, S. Karagiannis, 2016, Biotechnology progress.

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies

S. Tsoka, J. Spicer, S. Karagiannis, 2020, Frontiers in Immunology.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

G. Cook, P. Szlosarek, J. Spicer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

S. Beck, J. Shamash, L. Butcher, 2017, JAMA oncology.

The National Lung Matrix Trial of personalized therapy in lung cancer

C. Swanton, N. O'Rourke, L. Billingham, 2020, Nature.

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer

A. Tutt, A. Grigoriadis, J. Spicer, 2018, Clinical Cancer Research.

Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

A. Tutt, S. Pinder, A. Grigoriadis, 2018, Clinical Cancer Research.

Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma

Kristina M. Ilieva, I. Fentiman, J. Taylor‐Papadimitriou, 2015, Oncoimmunology.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain

M. Jamal-Hanjani, J. Spicer, Mariam Jamal-Hanjani, 2011, Clinical Cancer Research.

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

G. Demetri, S. Gwyther, M. Leach, 2013, Clinical Cancer Research.

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

R. Plummer, A. Futreal, M. Uttenreuther-Fischer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

J. Spicer, S. Rudman, 2010, Targeted Oncology.

A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel.

J. Spicer, S. Rudman, J. D. de Bono, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors

A. Harris, J. Spicer, E. Bone, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical A First-inMan Phase I and Pharmacokinetic Study on CHR-2797 ( Tosedostat ) , an Inhibitor of M 1 Aminopeptidases , in Patients with Advanced Solid Tumors

A. Harris, J. Spicer, E. Bone, 2009 .

Epidemiology of Lung Cancer

J. Spicer, D. Repana, 2017 .

Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR

E. Mclean, J. Spicer, K. Tobal, 2011, PloS one.

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

J. Spicer, D. Mukherji, 2009 .

Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.

J. Spicer, A. Nair, A. Billé, 2019, The Annals of thoracic surgery.

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.

D. Landau, J. Spicer, S. Papa, 2015, The Journal of thoracic and cardiovascular surgery.

Targeted therapies for non‐small cell lung cancer

J. Spicer, P. Harper, P. Harper, 2005, International journal of clinical practice.

The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase.

A. Ashworth, J. Spicer, S. Swift, 1999, Human molecular genetics.

Targeting folate receptor alpha for cancer treatment

Kristina M. Ilieva, A. Tutt, A. Grigoriadis, 2016, Oncotarget.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma.

J. Spicer, L. Lang-Lazdunski, T. Hardwick, 2011, Interactive cardiovascular and thoracic surgery.

Trends in incidence of small cell lung cancer and all lung cancer.

M. Peake, J. Spicer, H. Møller, 2012, Lung cancer.

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

J. Shamash, P. Szlosarek, J. Spicer, 2020, JTO clinical and research reports.

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

J. Spicer, D. Josephs, S. Karagiannis, 2019, Front. Immunol..

COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients

E. Sawyer, S. Irshad, J. Spicer, 2021, Cancers.

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

R. Plummer, Karen So, J. Spicer, 2015, Cancer Chemotherapy and Pharmacology.

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy

D. Landau, S. Barrington, J. Spicer, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

Kristina M. Ilieva, A. Tutt, J. Spicer, 2017, Oncoimmunology.

Regulation of the Wnt signalling component PAR1A by the Peutz–Jeghers syndrome kinase LKB1

A. Ashworth, J. Spicer, Darrin P. Smith, 2003, Oncogene.

Microdroplet Digital PCR: Detection and Quantitation of Biomarkers in Archived Tissue and Serial Plasma Samples in Patients with Lung Cancer

J. Spicer, K. Tobal, P. Cane, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR inhibition and more: a new generation growing up.

J. Spicer, D. Enting, 2012, Journal of thoracic disease.

Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial

Marilyn M. Li, Joshua L. Deignan, R. Butler, 2014, Journal of Clinical Pathology.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

R. Plummer, M. Toulmonde, A. Italiano, 2018, European journal of cancer.

Targeted therapies in non-small cell lung cancer

J. Spicer, F. Kyle, 2008, Cancer imaging : the official publication of the International Cancer Imaging Society.

A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).

J. Spicer, F. Farzaneh, L. Whilding, 2018 .

Abstract CT118: T4 immunotherapy of head and neck squamous cell carcinoma using pan-ErbB targeted CAR T-cells

J. Spicer, L. Whilding, J. Maher, 2017 .

Provision of cancer care during the COVID-19 pandemic

J. Spicer, S. Papa, C. Chamberlain, 2020, Nature Reviews Clinical Oncology.

Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma

Kristina M. Ilieva, F. Nestle, J. Spicer, 2014, Molecular Cancer Therapeutics.

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

D. Landau, E. Miles, J. Spicer, 2016, International journal of radiation oncology, biology, physics.

BRAF inhibitors: resistance and the promise of combination treatments for melanoma

Daniel C. Scotto, Kristina M. Ilieva, J. Spicer, 2017, Oncotarget.

Phase I/II Trial of Abiraterone Acetate (AA) in Estrogen Receptor (ERα) or Androgen Receptor (AR) Positive Metastatic Breast Cancer (MBC)

M. Dowsett, J. Bono, N. Dobbs, 2012 .

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours

M. Sawyer, W. Miller, J. Spicer, 2013, Cancer Chemotherapy and Pharmacology.

Therapeutic targets and new directions for antibodies developed for ovarian cancer

J. Spicer, D. Josephs, S. Karagiannis, 2016, mAbs.

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.

M. Mazumdar, H. Scher, D. Bajorin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart

J. Spicer, D. Josephs, M. Cooper, 2021, Oncoimmunology.

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Implications for Therapeutic Drug Monitoring

D. Fisher, R. Flanagan, J. Spicer, 2013, Therapeutic drug monitoring.

Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer

A. Tutt, S. Pinder, S. Tsoka, 2021, Cancer Research.

IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin

Kristina M. Ilieva, F. Villanova, F. Nestle, 2016, Scientific Reports.

Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.

A. Ciarrocchi, J. Spicer, A. Saxena, 2020, European journal of cancer.

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

J. Spicer, A. Awada, P. Barthélémy, 2015 .

A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.

G. Curigliano, J. Spicer, A. Awada, 2018 .

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields

Kristina M. Ilieva, A. Tutt, J. Spicer, 2017, Front. Immunol..

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

T. Daniels, M. Penichet, F. Nestle, 2009, Cancer Immunology, Immunotherapy.

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer

D. Dunlop, K. O'Byrne, L. Billingham, 2017 .

Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

R. Plummer, J. Spicer, D. Jodrell, 2013 .

A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.

R. Plummer, E. Frenkel, M. Jamal-Hanjani, 2012 .

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

M. Malim, A. Hayday, S. Irshad, 2021, medRxiv.

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology

Kristina M. Ilieva, A. Tutt, J. Spicer, 2018, The Journal of allergy and clinical immunology.

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

J. Galon, J. Spicer, F. Hermitte, 2021, Clinical Cancer Research.

OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

E. Schmidt, E. Felip, H. Gabra, 2021 .

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

G. J. M. Parker, A. Harris, G. Parker, 2011, Cancer Chemotherapy and Pharmacology.

National comparisons of lung cancer survival in England, Norway and Sweden 2001–2004: differences occur early in follow-up

L. Holmberg, F. Bray, M. Peake, 2010, Thorax.

A phase 1 study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumors.

R. Plummer, J. Spicer, V. Diéras, 2017 .

The impact of socioeconomic status on access to cancer clinical trials

D. Camidge, J. Spicer, S. Papa, 2014, British Journal of Cancer.

Hypertension and targeted therapy

J. Spicer, S. Chowdhury, P. Harper, 2006, Targeted Oncology.

Hypertension and targeted therapy

J. Spicer, S. Chowdhury, P. Harper, 2006, Targeted Oncology.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

N. Tunariu, W. Brugger, D. Talbot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

E. Karapanagiotou, J. Spicer, D. Josephs, 2022, Cancers.

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

E. Schmidt, E. Felip, H. Gabra, 2020 .

Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies.

M. Dowsett, A. Tutt, C. Swanton, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients

M. Peake, J. Spicer, R. Sullivan, 2018, Thorax.

Syddansk Universitet Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients

M. Peake, J. Spicer, R. Sullivan, 2018 .

The MARS feasibility trial : Conclusions not supported by data - Authors' reply

J. Peto, T. Treasure, D. Landau, 2011 .

Nedaplatin: a new platinum for squamous lung cancer?

J. Spicer, Yin Wu, 2015, The Lancet. Oncology.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Y. Drew, J. Machiels, Melissa L. Johnson, 2019, Clinical Cancer Research.

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

G. Nuovo, M. Coffey, K. Twigger, 2010, Clinical Cancer Research.

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

M. Uttenreuther-Fischer, J. Spicer, S. Rudman, 2013, Cancer Chemotherapy and Pharmacology.

The role of the HGF/Met axis in mesothelioma.

J. Spicer, J. Maher, Thivyan Thayaparan, 2016, Biochemical Society transactions.

Molecular imaging in clinical trials

M. O'Doherty, J. Spicer, D. Josephs, 2009, Targeted Oncology.

Design of a Phase I Clinical Trial to evaluate intra-tumoral delivery of ErbB-targeted CAR T-cells in locally advanced or recurrent Head and Neck Cancer

J. Spicer, J. Maher, S. Papa, 2013 .

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies

K. Twigger, V. Roulstone, R. Vile, 2021, Journal for ImmunoTherapy of Cancer.

etaxel in Patients with Advanced Cancer

G. Nuovo, M. Coffey, K. Twigger, 2010 .

A Phase I Study to Evaluate Systemic Wild-type Reovirus (REOLYSIN)(R) in Combination With Docetaxel in Patients With Advanced Malignancies

M. Coffey, B. Thompson, H. Pandha, 2008 .

Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer

B. Thompson, H. Pandha, J. Spicer, 2007 .

D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR

R. Plummer, A. Futreal, J. Spicer, 2007 .

Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.

R. Plummer, K. Kern, J. Spicer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.

Alex C. Williams, M. Parmar, M. Seckl, 2023, The Lancet. Oncology.

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009

M. Peake, J. Spicer, D. Baldwin, 2013, Thorax.

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

D. Camidge, J. Spicer, A. Mita, 2010 .

Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFRT790M mutation and small cell transformation

E. Karapanagiotou, G. Cook, E. Mclean, 2021 .

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells

Kristina M. Ilieva, A. Tutt, F. Nestle, 2018, Front. Immunol..

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

A. Tutt, J. Spicer, S. Karagiannis, 2020, Scientific Reports.

Targeting novel and established therapies for non-small cell lung cancer.

J. Spicer, S. Chowdhury, P. Harper, 2007, Cancer letters.

cell lung cancer : Results from a British Thoracic Oncology Group randomised phase III trial

K. O'Byrne, L. Billingham, M. Nicolson, 2017 .

A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)

K. Harrington, J. Spicer, M. Forster, 2019, Annals of Oncology.

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study

J. Spicer, F. Farzaneh, A. Santambrogio, 2023, Journal for ImmunoTherapy of Cancer.

Amplification and Over-Expression of the MDM2 Gene in Human Soft Tissue Tumours

C. Cooper, B. Gusterson, C. Fisher, 1997, Sarcoma.

A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

W. Guo, F. Khuri, E. Felip, 2013, Journal of Clinical Oncology.

A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

E. Schmidt, R. Holt, E. Felip, 2019, Journal of Clinical Oncology.

MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC

E. Schmidt, R. Holt, E. Felip, 2019, Journal of Thoracic Oncology.

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma

S. Tsoka, F. Fraternali, E. Diamandis, 2023, Nature communications.

FEASIBILITY PHASE OF THE MESOTHELIOMA AND RADICAL SURGERY (MARS) RANDOMISED CONTROLLED TRIAL COMPARING EXTRA-PLEURAL PNEUMONECTOMY (EPP) WITH NO EPP IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

J. Peto, T. Treasure, D. Landau, 2011 .

LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.

J. Spicer, A. Awada, J. Baurain, 2017 .

Effects of rhEPO on quality of life in anemic cancer patients

J. Spicer, S. Chowdhury, P. Harper, 2008 .

Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4

Kristina M. Ilieva, S. Tsoka, J. Downward, 2023, Nature communications.

An open, pharmacokinetic (PK) and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations

J. Spicer, T. Yap, A. Reid, 2007 .

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Kristina M. Ilieva, S. Canevari, U. Banerji, 2023, Nature communications.

J. Peto, T. Treasure, D. Landau, 2011, The Lancet. Oncology.

J. Spicer, T. Yap, A. Gualberto, 2010, British Journal of Cancer.

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

R. Plummer, T. Meyer, J. Rossi, 2020, Clinical Cancer Research.

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

A. Tutt, C. Caldas, E. Provenzano, 2023, Nature communications.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

R. Plummer, E. Frenkel, A. Italiano, 2016 .

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

G. Nuovo, M. Coffey, K. Twigger, 2010, Clinical Cancer Research.

Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer

Kristina M. Ilieva, S. Pinder, U. Banerji, 2020, Tumor Biology.

Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)

K. Harrington, J. Spicer, A. Espinasse, 2017 .

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Cellular immunotherapy for cancer: current concepts and clinical perspectives Monitoring immune responses and clinical trials: part II.

H. Pandha, J. Spicer, T. Plunkett, 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

V. Khoo, H. Pandha, S. Nair, 2007, The Journal of urology.

Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.

H. Pandha, J. Spicer, J. Spicer, 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer.

J. Spicer, M. van Schalkwyk, J. Maher, 2013, Human Gene Therapy Clinical Development.

Targeted therapy in cancer

James Spicer, Philip Charlton, J. Spicer, 2016 .

Drugs for Cancer

J. Spicer, J. Bono, 2013 .

A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET.

P. Marsden, S. Irshad, S. Barrington, 2010 .